McGirt Matthew J, Lynch John R, Blessing Robert, Warner David S, Friedman Allan H, Laskowitz Daniel T
Multidisciplinary Neuroprotection Laboratory, Medical Center, Duke University School of Medicine, Durham, NC 27710, USA.
Neurosurgery. 2002 Nov;51(5):1128-34; discussion 1134-5. doi: 10.1097/00006123-200211000-00005.
Endothelial damage and intimal proliferation occur in vasospastic cerebral arteries after subarachnoid hemorrhage (SAH). In the peripheral vasculature, endothelial damage increases intimal matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) levels, causing neointimal proliferation. We hypothesized that serum von Willebrand factor (vWF) (a marker of endothelial cell death), MMP-9, and VEGF levels could serve as prognostic markers in predicting the occurrence of cerebral vasospasm.
Venous serum vWF, MMP-9, and VEGF levels were prospectively measured daily, for 12 days or until the onset of vasospasm, for 45 consecutive patients admitted with SAH (n = 38) or admitted for elective aneurysm clipping (control subjects, n = 7). The development of transcranial Doppler flow velocities of more than 180 cm/s and/or new focal neurological deficits with angiographically confirmed vasospasm was considered the onset of vasospasm. To establish whether these markers were specific for vasospasm versus ischemia, blood samples were obtained from a concurrent group of 42 patients within 24 hours after stroke onset unrelated to SAH.
Fifty-seven percent of patients (22 of 38 patients) developed vasospasm, 4 to 11 days after SAH (median, 7 d). Mean peak serum vWF, MMP-9, and VEGF levels were increased in the SAH prevasospasm cohort, compared with the SAH nonvasospasm cohort (vWF, 5526 +/- 929 versus 4934 +/- 599 ng/ml, P = 0.01; MMP-9, 705 +/- 338 versus 438 +/- 154 ng/ml, P = 0.006; VEGF, 0.12 +/- 0.06 versus 0.06 +/- 0.06 ng/ml, P = 0.023). Mean peak vWF, MMP-9, and VEGF levels for the focal ischemia cohort (vWF, 4645 +/- 875 ng/ml, P = 0.01; MMP-9, 250 +/- 308 ng/ml, P = 0.001; VEGF, 0.03 +/- 0.04 ng/ml, P = 0.001) were markedly lower in comparison with the SAH prevasospasm cohort and were unchanged in comparison with the control cohort. vWF levels of more than 5500 ng/ml, VEGF levels of more than 0.12 ng/ml, and MMP levels of more than 700 ng/ml each independently increased the odds of subsequent vasospasm (18-, 20-, and 25-fold, respectively).
The development of cerebral vasospasm after SAH was preceded by increases in serum vWF, MMP-9, and VEGF levels. Increased serum vWF, MMP-9, and VEGF levels could accurately predict the onset of cerebral vasospasm after SAH. These factors were not elevated by SAH alone or in a separate cohort of patients with ischemic stroke, suggesting that these factors might play a role in the pathogenesis of human cerebral vasospasm.
蛛网膜下腔出血(SAH)后,脑血管痉挛时会出现内皮损伤和内膜增生。在周围血管系统中,内皮损伤会增加内膜基质金属蛋白酶-9(MMP-9)和血管内皮生长因子(VEGF)水平,导致新生内膜增生。我们推测血清血管性血友病因子(vWF)(内皮细胞死亡的标志物)、MMP-9和VEGF水平可作为预测脑血管痉挛发生的预后标志物。
对45例连续入院的SAH患者(n = 38)或择期动脉瘤夹闭术患者(对照组,n = 7),前瞻性地每日测量静脉血清vWF、MMP-9和VEGF水平,持续12天或直至血管痉挛发作。经颅多普勒血流速度超过180 cm/s和/或出现新的局灶性神经功能缺损且血管造影证实有血管痉挛被视为血管痉挛发作。为确定这些标志物对血管痉挛与缺血是否具有特异性,在与SAH无关的卒中发作后24小时内,从42例同期患者中采集血样。
57%的患者(38例中的22例)在SAH后4至11天(中位时间为7天)发生血管痉挛。与SAH无血管痉挛队列相比,SAH血管痉挛前队列的血清vWF、MMP-9和VEGF平均峰值水平升高(vWF:5526±929 ng/ml对4934±599 ng/ml,P = 0.01;MMP-9:705±338 ng/ml对438±154 ng/ml,P = 0.006;VEGF:0.12±0.06 ng/ml对0.06±0.06 ng/ml,P = 0.023)。局灶性缺血队列的vWF、MMP-9和VEGF平均峰值水平(vWF:4645±875 ng/ml,P = 0.01;MMP-9:250±308 ng/ml,P = 0.001;VEGF:0.03±0.04 ng/ml,P = 0.001)与SAH血管痉挛前队列相比明显较低,与对照组相比无变化。vWF水平超过5500 ng/ml、VEGF水平超过0.12 ng/ml和MMP水平超过700 ng/ml各自独立增加了后续血管痉挛的几率(分别为18倍、20倍和25倍)。
SAH后脑血管痉挛的发生之前血清vWF、MMP-9和VEGF水平升高。血清vWF、MMP-9和VEGF水平升高可准确预测SAH后脑血管痉挛的发作。这些因素在单独的SAH患者或缺血性卒中患者队列中未升高,表明这些因素可能在人类脑血管痉挛的发病机制中起作用。